# Sarcura

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sarcura

- Industry: Biotechnology
- Headquarters: Austria
- Website: www.sarcura.com
- Total disclosed funding: $10M
- Latest round: Seed (Nov 17, 2022)
- Investors on record: 7

## About

Based in Austria, and founded in 2019 by its CEO Daniela Buchmayr, and co-founders Dr. Erwin Gorjup, and Dr. Martin Fischlechner. Sarcura GmbH operates as a deep-tech company that develops an instrument platform for the manufacturing of advanced cell therapies. In November 2022, Sarcura GmbH raised EUR 7 million in seed funding co-led by Lansdowne Investment Company Cyprus Limited and IST Cube Management, with participation from HCVC and Tecnet Equity. As of November 2022, the company has a team of 20 people.

Sarcura GmbH offers an instrument platform that combines silicon chip technology and microfluidic processing to enable real-time process control and manipulation on a cellular level, enabling a fully automated and modular manufacturing system. The platform will help to treat metabolic or neurologic diseases.

The company plans to use the seed funding to fuel the development of its first system prototype.

## Funding rounds

- Seed, Nov 17, 2022, $7.2M — Tecnet Equity, HCVC, Nina Capital, Xista Science Ventures, NovaCapital, Lansdowne Investment Company Cyprus Limited, Axilium Holding
- Seed, Nov 19, 2020, $3M — Xista Science Ventures

## Investors

- Xista Science Ventures (https://capitalatlas.ai/funds/xista-science-ventures) — Seed
- Tecnet Equity (https://capitalatlas.ai/funds/tecnet-equity) — Seed
- HCVC (https://capitalatlas.ai/funds/hcvc) — Seed
- Nina Capital (https://capitalatlas.ai/funds/nina-capital) — Seed
- NovaCapital (https://capitalatlas.ai/funds/novacapital) — Seed
- Lansdowne Investment Company Cyprus Limited — Seed
- Axilium Holding — Seed